S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
Lowest-Rated Stocks  
NYSE:GSK

GSK - GSK Stock Forecast, Price & News

$35.35
+0.32 (+0.91%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.91
▼
$35.47
50-Day Range
$28.66
▼
$35.35
52-Week Range
$28.47
▼
$46.97
Volume
4.89 million shs
Average Volume
5.06 million shs
Market Capitalization
$71.89 billion
P/E Ratio
4.33
Dividend Yield
3.50%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.06mentions of GSK in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.29%
From $3.26 to $3.40 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

239th out of 1,034 stocks

Pharmaceutical Preparations Industry

98th out of 502 stocks

See Top Rated MarketRank™ Stocks Here
GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

November 30, 2022 | marketbeat.com
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk (GSK)
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment
December 3, 2022 | msn.com
BRIEF-GSK Says EMA Accepts Marketing Authorisation Application For Momelotinib
December 3, 2022 | msn.com
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
December 3, 2022 | americanbankingnews.com
GSK (NYSE:GSK) PT Lowered to GBX 1,550
December 2, 2022 | finance.yahoo.com
Should You Hold GSK plc (GSK) Shares?
December 1, 2022 | americanbankingnews.com
GSK (NYSE:GSK) Price Target Lowered to GBX 1,535 at Morgan Stanley
November 22, 2022 | finance.yahoo.com
UPDATE 2-GSK to stop selling blood cancer drug Blenrep in United States
November 22, 2022 | finance.yahoo.com
GSK to withdraw Blenrep’s U.S. marketing authorization after FDA request
November 14, 2022 | finance.yahoo.com
GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
November 9, 2022 | marketwatch.com
Hospital-Acquired Infection Control Market Analysis Geography Trends, Demand and Forecasts 2028| GSK, Merck, Pfizer
November 9, 2022 | barrons.com
GSK Shares Drop as Cancer Drug Disappoints
November 8, 2022 | finance.yahoo.com
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
November 7, 2022 | finance.yahoo.com
GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care
November 2, 2022 | finance.yahoo.com
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
October 27, 2022 | markets.businessinsider.com
GSK Decides Not To Progress With Submissions For Otilimab In Treatment Of Rheumatoid Arthritis
October 27, 2022 | markets.businessinsider.com
GSK: FDA Advisory Committee Supports Daprodustat Use In Adult Dialysis Patients With Anaemia Of CKD
October 27, 2022 | proactiveinvestors.com
GSK reports mixed outcome from meeting with US Food and Drug Administration
October 27, 2022 | reuters.com
GSK to skip regulatory submissions for experimental arthritis drug
October 26, 2022 | reuters.com
New GSK closer to first U.S. approval with anemia drug for patients on dialysis
October 26, 2022 | finance.yahoo.com
U.S. FDA panel backs GSK's anemia drug for kidney disease patients on dialysis
October 26, 2022 | finance.yahoo.com
UPDATE 1-U.S. FDA panel backs GSK's anemia drug for kidney disease patients on dialysis
October 26, 2022 | finance.yahoo.com
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
October 19, 2022 | nasdaq.com
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report? - Nasdaq
October 14, 2022 | nasdaq.com
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK - Nasdaq
October 13, 2022 | ft.com
GSK hails respiratory virus jab after positive trial results - Financial Times
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Ex-Dividend for 10/6 Dividend
8/18/2022
Dividend Payable
10/06/2022
Last Earnings
11/02/2022
Ex-Dividend for 1/12 Dividend
11/17/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Dividend Payable
1/12/2023
Next Earnings (Estimated)
2/08/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:GSK
CUSIP
N/A
CIK
1131399
Web
www.gsk.com
Phone
442080475000
Fax
44-20-8047-7807
Employees
90,096
Year Founded
2000

Profitability

EPS (Most Recent Fiscal Year)
$8.16
Trailing P/E Ratio
4.33
Forward P/E Ratio
10.84
P/E Growth
1.23
Net Income
$6.03 billion
Net Margins
37.88%
Pretax Margin
15.33%
Return on Equity
32.18%
Return on Assets
7.69%

Debt

Debt-to-Equity Ratio
2.22
Current Ratio
0.97
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$46.91 billion
Price / Sales
1.53
Cash Flow
$3.61 per share
Price / Cash Flow
9.78
Book Value
$5.05 per share
Price / Book
7.00

Miscellaneous

Outstanding Shares
2,033,680,000
Free Float
1,830,309,000
Market Cap
$71.89 billion
Optionable
Optionable
Beta
0.68

Social Links


Key Executives

  • Ms. Emma Natasha Walmsley (Age 52)
    CEO & Director
    Comp: $4.61M
  • Mr. Iain James MackayMr. Iain James Mackay (Age 60)
    CFO & Exec. Director
    Comp: $3.43M
  • Ms. Julie Brown (Age 60)
    Chief Financial Officer
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally JacksonMs. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. David Simon Redfern (Age 56)
    Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.

How have GSK shares performed in 2022?

GSK's stock was trading at $44.10 at the beginning of the year. Since then, GSK stock has decreased by 19.8% and is now trading at $35.35.
View the best growth stocks for 2022 here.

Are investors shorting GSK?

GSK saw a drop in short interest in November. As of November 15th, there was short interest totaling 11,250,000 shares, a drop of 15.8% from the October 31st total of 13,360,000 shares. Based on an average daily trading volume, of 6,330,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 0.6% of the company's stock are sold short.
View GSK's Short Interest.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our GSK earnings forecast.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) released its quarterly earnings data on Wednesday, November, 2nd. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.19. The pharmaceutical company had revenue of $9.22 billion for the quarter, compared to the consensus estimate of $7.75 billion. GSK had a net margin of 37.88% and a trailing twelve-month return on equity of 32.18%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a quarterly dividend on Wednesday, November 2nd. Shareholders of record on Friday, November 18th will be paid a dividend of $0.3695 per share on Thursday, January 12th. This represents a $1.48 annualized dividend and a dividend yield of 4.18%. The ex-dividend date of this dividend is Thursday, November 17th.
Read our dividend analysis for GSK.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.24 per share and currently has a dividend yield of 3.50%. The dividend payout ratio is 15.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.47% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.67 billion-$51.60 billion, compared to the consensus revenue estimate of $32.29 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by many different retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.60%), Price T Rowe Associates Inc. MD (0.55%), Renaissance Technologies LLC (0.46%), State Street Corp (0.37%), Two Sigma Investments LP (0.35%) and JTC Employer Solutions Trustee Ltd (0.23%).
View institutional ownership trends.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $35.35.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $71.89 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $8.16 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 12/4/2022 by MarketBeat.com Staff